Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- GE Healthcare Completes Takeover of Japan Licenses for 4 Imaging Agents from Daiichi Sankyo
March 4, 2020
- Kaken’s Efinaconazole Launched in Hong Kong
March 4, 2020
- Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
- Takeda’s ALK Drug Alunbrig Earns EU Backing for 1st Line NSCLC
March 3, 2020
- Takeda to Sell Latin American Non-Core Assets to Brazil’s Hypera Pharma
March 3, 2020
- Otsuka to Copromote Novartis’ Approval-Pending Entresto in Japan
March 3, 2020
- Sumitomo Dainippon Invests in Oncology Venture Fund
March 3, 2020
- Fujifilm’s US Subsidiary to Launch New iPS Cell Production Facility
March 3, 2020
- Toho Forges Capital Alliance with Kringle Pharma for Hepatocyte Growth Factor Development
March 3, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Crysvita Gets FDA’s Priority Review for Tumor-Induced Osteomalacia
March 2, 2020
- Takeda Files Midazolam Oral Solution for Status Epilepticus
March 2, 2020
- Takeda Submits Brigatinib in Japan as Second-Line Treatment for ALK-Positive NSCLC
March 2, 2020
- Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
March 2, 2020
- Nichi-Iko Takes Over Marketing Authorization for Etanercept Biosimilar from Kyowa
March 2, 2020
- Otsuka Joins Global Partnership to Eliminate TB
March 2, 2020
- Seikagaku to Acquire Canadian CDMO; Share Transfer Expected by End of March
March 2, 2020
- Takeda Snaps Up PvP Biologics, Gets Another Celiac Disease Drug
February 28, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…